Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives
| dc.rights.license | open | en_US |
| dc.contributor.author | DASTE, Amaury | |
| dc.contributor.author | LARROQUETTE, Mathieu | |
| dc.contributor.author | GIBSON, Nyere | |
| dc.contributor.author | LASSERRE, Matthieu | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | DOMBLIDES, Charlotte | |
| dc.date.accessioned | 2025-02-03T08:47:08Z | |
| dc.date.available | 2025-02-03T08:47:08Z | |
| dc.date.issued | 2024 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/204697 | |
| dc.description.abstractEn | Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatment of HNSCCs, mainly in combination with standard chemotherapy. This review focuses on the results of the main phase III studies evaluating ICIs in recurrent or metastatic HNSCCs. The efficacy and indications according to the PD-L1 status, the main predictive biomarker, are discussed. The results of trials assessing ICI efficacy for locally advanced disease, including the neoadjuvant setting are also discussed. Finally, therapeutic combinations that are potential treatments for HNSCCs, including ICIs and targeted therapies such as anti-EGFR agents, are presented. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | HPV | |
| dc.subject.en | PD-L1 | |
| dc.subject.en | Adjuvant | |
| dc.subject.en | Head and neck squamous cell carcinoma | |
| dc.subject.en | Immune checkpoint inhibitors | |
| dc.subject.en | Locally advanced | |
| dc.subject.en | Metastatic | |
| dc.subject.en | Neoadjuvant | |
| dc.subject.en | Predictive biomarker | |
| dc.subject.en | Treatment combination | |
| dc.title.en | Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.2217/imt-2023-0174 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| dc.identifier.pubmed | 38126161 | en_US |
| bordeaux.journal | Immunotherapy | en_US |
| bordeaux.page | 187 – 197 | en_US |
| bordeaux.volume | 16 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.issue | 3 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Immunotherapy&rft.date=2024&rft.volume=16&rft.issue=3&rft.spage=187%20%E2%80%93%20197&rft.epage=187%20%E2%80%93%20197&rft.au=DASTE,%20Amaury&LARROQUETTE,%20Mathieu&GIBSON,%20Nyere&LASSERRE,%20Matthieu&DOMBLIDES,%20Charlotte&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||